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Abstract 
Background: 
Attention-deficit hyperactivity disorder (ADHD) is a risk factor for development of 
substance use disorders. Treatment of ADHD with psychostimulants in patients on 
opioid maintenance treatment (OMT) has been restricted in Norway. We examined 
use of prescribed drugs for ADHD in OMT patients, and assessed co-medication with 
other psychotropics. 
Methods: 
Data were drawn from the nationwide Norwegian Prescription Database (NorPD), 
which includes all prescriptions filled at pharmacies. The study population was people 
≥18 years on OMT during 2008-2010.  
Results: 
In 2010, 6,116 patients received OMT and 2.8% of these patients also received 
ADHD drugs. This is seven times greater than in the gender- and age-specific 
general population of Norway. Prevalence was higher in the youngest patients, while 
there was no gender difference. Methylphenidate was the most commonly used drug 
for ADHD in OMT patients, followed by atomoxetine. 60% of OMT patients filled at 
least one prescription for antidepressants, anxiolytics or hypnotics and percentages 
were similar for users and non-users of ADHD drugs. 
Conclusion: 
Treatment with ADHD drugs was higher in OMT patients than expected from the 
general population, but was relatively low compared to the prevalence of ADHD in 
patients with substance use disorders reported in the literature.  
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1 Introduction 
Attention-deficit hyperactivity disorder (ADHD) is reported as a risk factor for 
developing a substance use disorder (SUD) [1;2]. The link between ADHD and SUD 
has a familial association also, as children of parents that suffer from SUD have 
higher rates of several mental disorders, including ADHD [3;4]. SUD patients who 
have comorbid ADHD tend to have initiated illegal drug use at an earlier age and 
have a reduced likelihood of going into remission, compared to SUD patients without 
ADHD [5-8]. Comorbid ADHD is associated with greater addiction severity, lower 
quality of life and a greater risk of having other psychiatric disorders [8-11]. There are 
few studies of the effects of ADHD in SUD populations like opioid-dependent 
patients, and there is great variation in the estimated prevalence of ADHD [11].  
 
Although methylphenidate and other ADHD drugs are proven to be effective for 
treating ADHD, studies on such treatment in SUD populations are few, especially on 
patients receiving opioid-maintenance treatment (OMT). Controlled and uncontrolled 
studies do not give supporting evidence that pharmacotherapy for ADHD is effective 
when used in SUD populations [8;12]. A summary report on experience from Norway 
on treating ADHD in opioid-maintained populations indicate some positive results 
[14], but larger studies specifically designed to study the effectiveness and safety of 
combined treatment of ADHD and opioid-dependence are clearly needed. The 
objective of the present study was to give an overview of the use of drugs for ADHD 
in adult patients on OMT in Norway by using the nationwide Norwegian Prescription 
Database (NorPD).  
 
Aims of the study: 
To examine 1) annual prevalence of prescribed drug use for ADHD in OMT patients 
during 2008-2010; 2) annual prevalence of prescribed drug use for ADHD in OMT 
patients compared to the prevalence in the Norwegian general population; 3) type of 
prescribed drugs used for ADHD; 4) persistence of use of prescribed ADHD drugs in 
OMT patients; and 5) co-medication with other psychotropic drugs among users and 
non-users of prescribed ADHD drugs. 
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2 Materials and methods 
2.1 Study setting 
The OMT programme was implemented on a national level in 1998, and is integrated 
into the tax-supported public health service covering all Norwegian citizens. The 
programme has a multimodal approach for treating opioid-dependent patients and 
involves the specialist healthcare system, general practitioners (GPs) and the social 
services. The programme was quite restrictive during the first 12 years [15], but more 
liberal government regulations and national guidelines were implemented in 2010 
[16;17]. The aim of the programme is to improve the patients’ quality of life, facilitate 
changes in lifestyle, as well as harm reduction. The regulation acknowledges that it 
may not be possible for all patients to attain abstinence from opioid use. The 
indication for treatment is opioid-dependence and there is no longer any minimum 
age for inclusion in the programme. Termination of the drug treatment without the 
patient’s consent should be considered only if it is harmful to the patient. Initiation 
and termination of OMT treatment is managed by the specialized regional OMT 
centres. GPs have a central role in the regular follow-up of patients once they are 
stabilized, including prescribing of drugs. GPs managed the prescribing of OMT 
drugs for two-third of the patients in 2010, however with substantial regional 
differences [18]. Most patients take the OMT drugs under supervision, most 
frequently by pharmacy or social services personnel. Only patients that have been 
stabilized on treatment over a longer period may bring OMT drugs home and take the 
drug without supervision, and for a maximum of 7 days [17;18]. 
2.2 Data source: the Norwegian Prescription Database (NorPD) 
Data were drawn from the Norwegian Prescription Database (NorPD), which covers 
the entire population (~4.9 million) of Norway since 2004 [19]. NorPD contains 
information on all prescribed drugs, reimbursed or not, that have been dispensed 
from pharmacies to patients in ambulatory care. Prescriptions can be linked to 
individual patients by the personal identity number (encrypted identity). Drugs are 
classified according to the Anatomical Therapeutic Chemical classification system 
(ATC) [20]. Variables included in this study were the patient’s unique identity number, 
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gender, age, date of dispensing the drug, ATC code and the Nordic article number 
for drug packages.  
2.3 Study population: patients receiving OMT drugs 
The study population included people ≥18 years who received OMT drugs on 
prescription during 2008-2010. Since 2008, OMT drugs have mainly been dispensed 
by pharmacies and are registered on the individual patient in NorPD. OMT drugs 
used when patients are admitted in institutions are not registered on an individual 
level in NorPD. Methadone, especially tablets, may be used for pain relief in Norway. 
To minimize inclusion of non-OMT patients in our study population, patients that 
exclusively received methadone as tablets were not included (258 patients) [21]. In 
2010, we identified 6,116 OMT patients ≥18 years in NorPD, while one patient aged 
17 years was excluded from analysis (Table 1).  
2.4 Definition of OMT drugs, ADHD drugs, and other psychotropic drugs 
OMT drugs: Methadone mixture (ATC code N07BC02), buprenorphine tablets 
(N07BC01), and buprenorphine-naloxone combined tablets (N07BC51). Methadone 
tablets were not included when defining the study population of OMT patients. 
ADHD drugs: Methylphenidate (N06BA04), atomoxetine (N06BA09), racemic 
amphetamine (N06BA01), and dexamphetamine (N06BA02). ADHD drugs may also 
be used for narcolepsy. We checked that none of the OMT patients in 2010 received 
ADHD drugs for narcolepsy by examining the drug reimbursement codes (ICD-10 
and ICPC-2), which have been included in NorPD from 2008 and fully implemented 
from 2009.   
Other psychotropic drugs: Antidepressants (N06A), anxiolytics (N05B), and hypnotics 
(N05C). 
2.5 Prescribing restrictions for narcotic drugs 
Prescribing of narcotic drugs requires a specific prescription form («class A drug 
prescription»), and applies to strong opioids (all OMT drugs) and psychostimulants 
(all ADHD drugs except atomoxetine). Prescribing of OMT drugs is strictly regulated 
in the OMT programme, and prescribing of psychostimulants is also restricted; 
specialists in psychiatry, paediatrics or neurology can prescribe to all patients after 
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given a general permission, while other physicians have to apply for permission to 
prescribe psychostimulants to specific, named patients. Unlike the psychostimulants 
used in the treatment of ADHD, atomoxetine is not defined as a narcotic drug and 
does not have the same prescribing restrictions. If concomitant use of 
psychostimulants with OMT drugs is considered appropriate for a patient, a specific 
application for such use is required [22].  
2.6 Analysis strategy and statistics 
Data for the period 2008-2010 were retrieved from NorPD and analysed as one-year 
cross sections. The main analysis was based on OMT patients in 2010. For the 
calculation of Standardized Morbidity Ratio (O/E), the observed number of patients 
treated with ADHD drugs in 2010 was compared to the expected number, by applying 
the prevalence of ADHD drug use for each gender- and age- specific group in the 
Norwegian general population (standard population) on the one-year age- and 
gender- specific distribution in the OMT population (study population). The 
denominator for the prevalence in the standard population is the gender- and age- 
specific total population of Norway, retrieved from Statistics Norway. Age-adjusted 
odds ratios (OR) for use of antidepressants, anxiolytics and hypnotics for users 
versus non-users of ADHD drugs among OMT patients were estimated by logistic 
regression. Data analysis was performed with Stata version 11.  
3 Results 
3.1 Annual prevalence of ADHD drugs used by OMT patients 
The number of patients that received at least one prescription for OMT drugs during 
one calendar year increased over the period 2008-2010 in both men and women 
(Table 1). In 2010, 6,116 patients received OMT drugs, and 170 (2.8%) patients also 
received ADHD drugs the same year. The proportion receiving ADHD drugs in 2010 
was higher in the youngest men and women, but there was no gender difference 
within the two age strata (Table 2).  
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3.2 Annual prevalence of ADHD drug use in OMT patients compared to the 
general population of Norway 
The gender- and age- specific prevalence of ADHD drug use in the Norwegian 
general population was used as a reference in Table 2. The prevalence of ADHD 
therapy was seven times greater among OMT patients than expected from the 
general population, and this increase was observed within different gender and age 
strata (O/E range 5.8-7.5). 
3.3 Type of ADHD drugs used by OMT patients 
Table 3 presents the type of ADHD drugs used by the 170 OMT patients who 
received ADHD drugs in 2010. Methylphenidate was by far the most commonly used 
ADHD drug, followed by atomoxetine. Delayed release formulations of 
methylphenidate were more commonly used than immediate release formulations. 
Racemic amphetamine and dexamphetamine were used by 15 patients. In total, 138 
patients (81%) received at least one of the psychostimulants (methylphenidate, 
amphetamine or dexamphetamine) and 5 of these patients received two different 
psychostimulants. 
3.4 Persistence of use of ADHD drugs in OMT patients 
In total 4,020 patients received OMT drugs in all three years 2008-2010. In this 
group, 110 patients received drugs for ADHD in 2008. 81 (74%) of these received 
ADHD drugs also in 2009, while 62 (56%) received these drugs all three years. 
Corresponding figures in the general population with the same gender and age 
distribution as the OMT population and who had received ADHD drugs in 2008 were 
80% and 67%, respectively.  
3.5 Co-medication with other psychotropic drugs  
Co-medication with other psychotropic drugs was common in OMT patients (Table 4). 
In total, 60% of the OMT patients received at least one prescription for 
antidepressants, anxiolytics or hypnotics in 2010. Odds ratios (OR) for use of 
psychotropics in users versus non-users of ADHD drugs did not show any consistent 
pattern for higher or lower use of psychotropics. The only statistically significant OR 
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was that fewer of the female users of ADHD drugs received anxiolytics than female 
non-users (age-adjusted OR 0.43 [0.23-0.81]). 
4 Discussion 
The main finding of this nationwide study in Norway was that 2.8% of patients on 
OMT in the outpatient setting received ADHD drugs in 2010. This is seven times 
higher than expected from ADHD drug use in the general population. The prevalence 
was higher in the youngest patients, while there was no gender difference. Co-
medication with antidepressants, anxiolytics and hypnotics was high in the OMT 
population but showed no consistent pattern between ADHD drug users and non-
users. 
 
An overall ADHD prevalence of 23% in SUD patients (different types of substances) 
was reported in a meta-analysis [23]. There are few studies of ADHD in opioid-
dependent patients but, as summarized by Carpentier et al. [11], prevalence in the 
range 11-29 % have been reported in clinical, treatment-seeking populations from 
Switzerland, Germany and the USA. One study reported an ADHD prevalence of 4-
5%, but the opioid- and/or cocaine- dependant study population was not necessarily 
seeking treatment [7]. Carpentier and co-workers [11] also conducted their own 
comprehensive study in the Netherlands among patients in long-term methadone 
maintenance treatment. 35% had childhood ADHD and 25% had ADHD persisting 
into adulthood, while an additional 6-7% had suspected ADHD.  
 
These prevalence estimates for ADHD in opioid-dependent patients from four 
different countries are high compared to the percentage of OMT patients who 
received pharmacotherapy for ADHD in Norway (2.8%). Deleterious effects of ADHD 
on outcomes of SUD have been reported, but there is limited evidence of the benefits 
and harm for treatment with different ADHD drugs in SUD populations, and results 
are conflicting [8;12-14]. Risk of misuse and diversion of psychostimulants may 
contribute to restrictive pharmacotherapy, although this may be less of a problem in 
the context of therapeutic use and with slow release formulations [8;14]. Norwegian 
guidance on treatment of ADHD has not recommended concomitant use of 
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psychostimulants and OMT drugs. In addition to the general restrictions for 
prescribing psychostimulants, physicians need to apply for a permit for a specific 
patient before initiating concomitant treatment with psychostimulants and OMT drugs 
[22]. Psychostimulants have only been sanctioned for use after three months of 
documented abstinence from drug abuse but may be considered earlier for individual 
patients admitted in institutions. Permission for concomitant use of OMT and 
psychostimulants has been granted to a few projects that were established to 
evaluate the effects of this treatment option. A conference evaluating these projects 
has been arranged and the conference summary report recommends that 
psychostimulants should be a treatment option offered also to OMT patients [14].  
 
A further explanation of the relatively low prevalence of ADHD drug use could be that 
patients with ADHD are less able to comply with the strict OMT programme due to 
nature of the disease and its symptoms. Thus, higher shares of the OMT patients 
with ADHD may have dropped out of the programme than in OMT patients without 
ADHD. Our prevalence estimate of ADHD drug use must be interpreted in light of 
these issues with ADHD treatment in this patient group, as well as the possibility of 
undiagnosed ADHD in this patient group. Thus, the prevalence of use of prescribed 
ADHD drugs reported in the present study cannot be considered as a prevalence 
estimate of ADHD in OMT patients.  
 
There are more men than women in the OMT programme, but no gender difference 
was observed in the proportion of patients receiving drugs for ADHD in this adult 
population. This is also observed in the general population of Norway; while the 
prevalence of use of ADHD drugs is markedly higher in boys during childhood and 
adolescence, there is no gender difference in adults and the prevalence levels are 
substantially lower at this age [24]. 
 
For patients who are abstinent from drug abuse for at least three months, 
methylphenidate is the treatment of choice for ADHD in Norwegian OMT patients 
[22]. Racemic amphetamine and dexamphetamine may have a higher risk of relapse 
of drug abuse and is currently not recommended in previous drug abusers [22]. 
However, some experts have proposed that amphetamine and dexamphetamine 
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should be considered if methylphenidate does not have sufficient effect [14]. 
Atomoxetine, which is not classified as a narcotic drug, should also be considered in 
drug abusers even though it is only approved for use in children and adolescents with 
ADHD [22]. According to NorPD data from 2010 for the entire Norwegian population 
20 years or older [24], 87% of ADHD drug users received methylphenidate and 9% 
received atomoxetine, compared to respectively 75% and 19% in the OMT population 
(Table 3). Thus, the guidance for ADHD treatment of this population seems to have 
had some impact on the type of drugs that are prescribed.  
 
We found that co-medication with other psychotropic drugs, some with potential for 
misuse, was common in OMT patients. However, use of other psychotropics was not 
consistently higher or lower in users of ADHD drugs compared to non-users. Thus, 
our results do not provide a clear indication of different rates of psychiatric 
comorbidity in ADHD patients compared to the patients without ADHD. This high 
prevalence of co-medication with psychotropics has also been reported in previous 
NorPD studies in OMT patients. Hartz et al. [25] found a prevalence for 
antidepressants of 22%, with equal shares in men and women. Fredheim et al. [26] 
reported that 12% of OMT patients received prescriptions for another opioid in 
addition to the opioid used for OMT. Bramness and Kornør [27] reported a 
prevalence of 40% for prescribed benzodiazepines in OMT patients in 2005 and the 
prevalence of use was higher in women than in men. The annual report for the 
Norwegian OMT programme for 2010 also reported high use of benzodiazepines 
[18], as 23% of OMT patients were reported to have received prescribed 
benzodiazepines, while 41% were reported to use benzodiazepines during the last 
four weeks (prescribed and/or illegal)  [18]. The national guidelines states that 
benzodiazepines should not be prescribed to OMT patients [17]. 
 
Strengths of the present study are that it is based on high quality data from a 
nationwide prescription database covering drugs dispensed from Norwegian 
pharmacies to all individuals in ambulatory care. Since 2008, OMT drugs have mainly 
been provided by pharmacies for all patients except when they are admitted to 
institutions. Thus, use of these drugs has been registered in NorPD for individual 
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patients (with encrypted personal identity number), and enable us to study the 
concomitant use of OMT and ADHD drugs on a nationwide scale.  
 
The study population of OMT patients was identified by studying dispensed 
prescriptions for OMT drugs. We excluded patients that only received methadone 
tablets, as these are more likely to be Using methadone for treatment of pain. 
Furthermore, all physicians can in principle initiate use of OMT drugs before applying 
for enrolment in the OMT programme to stabilize specific patients during critical 
situations. Thus, some patients not enrolled in the OMT programme may have been 
included in our study and contribute to a slightly higher number of OMT patients. On 
the other hand, some patients admitted to institutions may only have received OMT 
drugs from the institutions, and are therefore not registered in NorPD. In 2010, 6,015 
patients were enrolled in the OMT programme at the end of the year [18]. This 
corresponds quite well with our NorPD data that identified 6,116 patients who 
received OMT drugs during the same year.  
 
We did not have access to diagnostic information or other clinical information like the 
extent of impairment from ADHD, which is important when deciding treatment for 
ADHD. The appropriateness of ADHD drug use could not be addressed. 
Furthermore, we could not assess whether patients were stabilized on the OMT 
drugs and whether they used any illegal substances. When using data from 
prescription databases, one does not know if the dispensed drugs are actually taken 
by the patients. It is common in Norway that OMT drugs have to be taken in the 
presence of pharmacy personnel or others, while taking psychostimulants is not 
supervised and diversion of these drugs to the illegal market is possible.  
 
The OMT programme is multimodal and the use of OMT drugs should enable 
patients to utilize the important psychosocial support provided through the 
programme. Diagnosing and treating ADHD in drug abusers is challenging and 
requires careful consideration of benefits and harm for the individual patient, but may 
assist in preventing relapse of drug abuse. Close monitoring of the use of 
psychostimulants is important for this patient group. 
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Table 1. Patients on opioid maintenance treatment (OMT) and OMT patients 
receiving drugs for attention-deficit hyperactivity disorder (ADHD) in 2008-2010.  
Norwegian Prescription Database (NorPD). 
 
 
 
  
OMT OMT OMT
Year N n % 95% CI N n % 95% CI N n % 95% CI
2008 3,473 104 3.0 2.5-3.6 1,502 31 2.1 1.4-2.9 4,975 135 2.7 2.3-3.2
2009 3,847 121 3.1 2.6-3.8 1,648 50 3.0 2.3-4.0 5,495 171 3.1 2.7-3.6
2010 4,316 120 2.8 2.3-3.3 1,800 50 2.8 2.1-3.6 6,116 170 2.8 2.4-3.2
Men Women Total
 ADHD ADHD ADHD
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Table 2. Observed number (O), prevalence (%), and expected number (E) receiving 
drugs for attention-deficit hyperactivity disorder (ADHD) in patients on opioid 
maintenance treatment (OMT) in 2010.  
Standard population: population of Norway ≥18 years in 2010.   
Norwegian Prescription Database (NorPD).  
 
 
 
  
All All
N n % N O % 95% CI E O/E 95% CI
Total, 18+ yrs 3,805,931 14,077 0.37 6,116 170 2.8 2.4-3.2 25 6.9 5.9-8.1
Men
18-39 yrs 734,750 5,773 0.79 1,780 74 4.2 3.3-5.2 10 7.3 5.8-9.2
40+ yrs 1,154,737 1,858 0.16 2,536 46 1.8 1.3-2.4 7 6.4 4.7-8.5
Women
18-39 yrs 704,849 4,659 0.66 843 33 3.9 2.7-5.5 4 7.5 5.2-10.5
40+ yrs 1,211,595 1,787 0.15 957 17 1.8 1.1-2.9 3 5.8 3.4-9.4
Standard population
ADHD
OMT population
ADHD
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Table 3. Type of drugs for attention-deficit hyperactivity disorder (ADHD) received by 
170 patients on opioid maintenance treatment (OMT) in 2010.  
Norwegian Prescription Database (NorPD). 
 
 
  
18-39 yrs 40+ yrs 18-39 yrs 40+ yrs
N=74 N=46 N=33 N=17
n n n n n % 95% CI
Methylphenidate 60 33 23 12 128 75.3 68.0-81.4
Delayed release formulation** 50 26 20 10 106 62.4 54.6-69.7
Immediate release formulation** 20 13 11 3 47 27.6 21.1-35.0
Atomoxetine 13 6 8 5 32 18.8 13.4-25.7
Racemic amphetamine 0 2 0 0 2 1.2 0.2-4.6
Dexamphetamine 5 5 2 1 13 7.6  4.3-13.0
Two types of ADHD drugs* 4 0 0 1 5 2.9 1.1-7.1
* Received two types of ADHD drugs during 2010 (methylphenidate, atomoxetine, racemic amphetamine, 
or dexamphetamine) and are counted on both of the drugs they received.
** Numbers in italics give details on the type of formulation of methylphenidate that patients received during 
2010 (some patients received both types of formulations).
N=170
Men Women Total
18+ yrs
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Table 4. Co-medication with psychotropics in patients on opioid maintenance 
treatment (OMT), with or without use of drugs for attention-deficit hyperactivity 
disorder (ADHD) in 2010.  
Norwegian Prescription Database (NorPD). 
 
 
n % n % OR*
Men
OMT patients 120 4,196
Psychotropics** 74 62 52 - 70 2,480 59 58 - 61 1.13 0.78 - 1.64
Antidepressants 30 25 18 - 34 849 20 19 - 22 1.27 0.83 - 1.93
Anxiolytics 50 42 33 - 51 1,865 44 43 - 46 0.90 0.62 - 1.30
Hypnotics 45 38 29 - 47 1,259 30 29 - 31 1.40 0.96 - 2.04
Women
OMT patients 50 1,750
Psychotropics** 25 50 36 - 65 1,074 61 59 - 64 0.67 0.39 - 1.18
Antidepressants 14 28 16 - 43 384 22 20 - 24 1.40 0.72 - 2.62
Anxiolytics 13 26 15 - 40 820 47 45 - 49 0.43 0.23 - 0.81
Hypnotics 12 24 13 - 38 538 31 29 - 33 0.76 0.40 - 1.49
Received ADHD drugs Odds Ratio of 
receiving 
psychotropicsYes  No
** Received at least one of the psychotropic drugs in 2010.
* Age-adjusted Odds Ratio (OR) for use of psychotropics in users versus 
   non-users of ADHD drugs among all OMT patients.
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